Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in
recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is
to evaluate the efficacy of anlotinib.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University